Tranylcypromine hemisulfate is a irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) IC50
< 2 mM1,2.
Tranylcypromine treatment of P19 embryonal carcinoma cells resulted in global
increase of H3K4 methylation along with transcriptional derepression of two
BHC110 target genes, Egr1 and Oct4. When combined with CHIR99021, induces the
generation of human-induced pluripotent stem cells in the absence of exogenous
Sox23. Reduces proliferation,
cell cycle progression and invasiveness of endometriotic stromal cells4.
Upregulates CD86 expression in THP1 cells5. Cell permeable and
active in vivo.
Physical Properties: White powder
• 1/2 H2SO4
Analysis: >98% (TLC); NMR
Solubilization: May be dissolved in water (25 mg/ml)
Storage: Store desiccated as
supplied at ambient temperature for up to 2 years. Store solutions at -20°C for up to 1 month.